Aptocrom Inc

Aptocrom Inc's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 2.97, suggesting it can cover its short-term obligations but with limited excess capacity. Free cash flow is negative at -5.5 billion KRW, driven by capital expenditures of -14.09 million KRW and operational cash flow of 2.44 billion KRW. Profitability metrics show a challenging performance, with a return on equity of -1.81% and a return on assets of -1.73%. These figures fall significantly below the industry median for pharmaceutical companies, which typically report positive ROE and ROA. The company's operating income is negative at -8.81 billion KRW, and net income is also negative at -5.56 billion KRW, indicating a need for operational restructuring or cost optimization. The company's revenue is distributed across three segments: Pharmaceuticals, Insulation, and Rental. While the pharmaceutical segment is the primary business, the insulation and rental segments contribute to diversification. However, the financial snapshot does not provide specific revenue breakdowns by segment, making it difficult to assess the concentration of risk or growth potential within each business line. Growth trajectory is uncertain, as the company reported a negative net income and operating income in the latest financial period. The outlook for the current fiscal year does not provide specific numeric deltas, but the negative free cash flow and operating losses suggest a need for strategic interventions to reverse the trend. Historical revenue data is not provided, but the current financial performance indicates a potential decline in growth. Risk factors include liquidity constraints, as the company has negative net cash after subtracting total debt. The risk assessment indicates a low dilution potential, but the negative free cash flow and operating losses may necessitate future capital raising, which could lead to share dilution. The company's financial structure and performance suggest a need for careful monitoring of liquidity and profitability metrics. Recent events include the company's rebranding from AP Healthcare Inc to Aptocrom Inc, reflecting a strategic shift in its business focus. The 10-K filing for 2023 provides a detailed overview of the company's financial performance and risk factors, which are essential for understanding its current position and future prospects.